Novel KPC-2 variants and epidemic ST463 clones underlie ceftazidime/avibactam resistance in carbapenem-resistant <i>Pseudomonas aeruginosa</i>.

ABSTRACT: Carbapenem-resistant Pseudomonas aeruginosa (CRPA) presents a serious clinical challenge due to limited treatment options. Ceftazidime-avibactam (CZA) is a critical last-resort agent against multidrug-resistant Gram-negative pathogens; however, resistance is emerging, particularly mediated by bla_KPC variants. In this study, we investigated the prevalence and mechanisms of CZA resistance among CRPA isolates collected from two tertiary hospitals in Hangzhou between 2021 and 2022. A total of 273 non-duplicate CRPA isolates were screened, among which 13.9% (38/273) exhibited CZA resistance (MIC ≥ 16 µg/mL). Whole-genome sequencing revealed that resistant strains were highly resistant to carbapenems, cephalosporins, and aztreonam but retained partial susceptibility to a

SUBMITTER: Hu Y 

PROVIDER: S-EPMC12772382 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature